Vasculopathy in scleroderma

Seminars in Immunopathology

Volumn 37, Issue 5, 2015, Pages 489-500

  Asano, Yoshihide ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis; Cell adhesion molecules; Endothelial function; Endothelial to mesenchymal transition; Systemic sclerosis; Vasculogenesis

Indexed keywords

BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE;

BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; CELL INFILTRATION; CELL PROLIFERATION; DISEASE ACTIVITY; DISEASE MODEL; DRUG EFFECT; DRUG PULSE THERAPY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FIBRINOLYSIS; GENETIC CODE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SKIN FIBROSIS; TH17 CELL; TH2 CELL; VASCULAR DISEASE; VASCULAR REMODELING; ANIMAL; AUTOIMMUNITY; COMPLICATION; IMMUNOLOGY; MOUSE; SYSTEMIC SCLEROSIS;

ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 84940889699     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-015-0505-5     Document Type: Review

References (118)

1. Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii3–iii7
2. Asano Y (2010) Future treatments in systemic sclerosis. J Dermatol 37:54–70
3. Broen JC, Radstake TR, Rossato M (2014) The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 10:671–681
4. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263
5. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Investig 98:785–792
6. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L (2005) Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 64:1233–1235
7. Ihn H (2005) Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 7:156–162
8. Distler JH, Gay S, Distler O (2006) Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii26–iii27
9. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603–610
10. Rabquer BJ, Koch AE (2012) Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 14:56–63
11. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989–2003
12. Takahashi T, Asano Y, Amiya E, Hatano M, Tamaki Z, Takata M et al (2014) Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis. Mod Rheumatol 24:106–111
13. Cerinic MM, Valentini G, Sorano GG, D’Angelo S, Cuomo G, Fenu L et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285–295
14. Taniguchi T, Asano Y, Akamata K, Noda S, Takahashi T, Ichimura Y et al (2015) Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthr Rheumatol 67:517–526
15. Ihn H (2008) Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 49:103–113
16. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y et al (2013) Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 182:192–205
17. Wang Y, Fan PS, Kahaleh B (2006) Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 54:2271–2279
18. Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L et al (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751–1758
19. Giacomelli R, Matucci-Cerinic M, Cipriani P, Ghersetich I, Lattanzio R, Pavan A et al (1998) Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 41:327–334
20. Kahaleh MB, Fan PS, Otsuka T (1999) Gammadelta receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 91:188–195
21. Hill MB, Phipps JL, Cartwright RJ, Milford Ward A, Greaves M, Hughes P (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106:491–497
22. Rosenbaum J, Pottinger BE, Woo P, Black CM, Loizou S, Byron MA et al (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450–456
23. Salojin KV, Le Tonquèze M, Saraux A, Nassonov EL, Dueymes M, Piette JC et al (1997) Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 102:178–185
24. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550–2562
25. Mihai C, Tervaert JW (2010) Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis 69:319–324
26. Park C, Kim TM, Malik AB (2013) Transcriptional regulation of endothelial cell and vascular development. Circ Res 112:1380–1400
27. Fischer C, Schneider M, Carmeliet P (2006) Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis. Handb Exp Pharmacol 176:157–212
28. Dimmeler S, Zeiher AM, Schneider MD (2005) Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 115:572–583
29. Prater DN, Case J, Ingram DA, Yoder MC (2007) Working hypothesis to redefine endothelial progenitor cells. Leukemia 21:1141–1149
30. Estes ML, Mund JA, Ingram DA, Case J (2010) Identification of endothelial cells and progenitor cell subsets in human peripheral blood. Curr Protoc Cytom Chapter 9:Unit 9.33.31-11.
31. Richardson MR, Yoder MC (2011) Endothelial progenitor cells: quo vadis? J Mol Cell Cardiol 50:266–272
32. Yamaguchi Y, Okazaki Y, Seta N, Satoh T, Takahashi K, Ikezawa Z et al (2010) Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Res Ther 12:R205
33. Yamaguchi Y, Kuwana M (2013) Proangiogenic hematopoietic cells of monocytic origin: roles in vascular regeneration and pathogenic processes of systemic sclerosis. Histol Histopathol 28:175–183
34. Lau LF (2011) CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci 68:3149–3163
35. Grote K, Salguero G, Ballmaier M, Dangers M, Drexler H, Schieffer B (2007) The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. Blood 110:877–885
36. Saigusa R, Asano Y, Taniguchi T, Yamashita T, Takahashi T, Ichimura Y et al (2015) A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis. Exp Dermatol 24:127–132
37. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:R11
38. Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G, Bielecki M, Krasowska D (2011) Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford) 50:746–755
39. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK et al (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 3, e1452
40. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G et al (2010) Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 176:1983–1998
41. Noda S, Asano Y, Takahashi T, Akamata K, Aozasa N, Taniguchi T et al (2013) Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 52:790–799
42. Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T et al (2012) A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One 7, e32272
43. Takahashi T, Asano Y, Noda S, Aozasa N, Akamata K, Taniguchi T et al (2015) A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement, and renal dysfunction in systemic sclerosis. Br J Dermatol. doi:10.1111/bjd.13779
44. Thalgott J, Dos-Santos-Luis D, Lebrin F (2015) Pericytes as targets in hereditary hemorrhagic telangiectasia. Front Genet 6:37
45. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C et al (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45:694–702
46. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y et al (2010) Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 185:2502–2515
47. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC et al (2010) Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 12:R128
48. Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I et al (2013) Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Mod Rheumatol 23:1151–1157
49. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275–284
50. Yang X, Yang J, Xing X, Wan L, Li M (2014) Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 16:R4
51. Sato S, Hasegawa M, Takehara K (2001) Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27:140–146
52. Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, Makino T et al (2012) Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 188:3573–3583
53. Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim FA, Dayer JM (1998) Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 41:2039–2047
54. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A et al (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48:2593–2604
55. Chizzolini C (1999) T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 21:431–450
56. Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K et al (1997) Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 36:1270–1275
57. Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GC (1993) Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68:88–92
58. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K (1998) Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 37:1188–1192
59. Shahin AA, Anwar S, Elawar AH, Sharaf AE, Hamid MA, Eleinin AA et al (2000) Circulating soluble adhesion molecules in patients with systemic sclerosis: correlation between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and impaired left ventricular diastolic function. Rheumatol Int 20:21–24
60. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2005) Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 24:111–116
61. Kizu A, Medici D, Kalluri R (2009) Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol 175:1371–1373
62. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E et al (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13:952–961
63. Li J, Qu X, Bertram JF (2009) Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol 175:1380–1388
64. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T et al (2010) Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 43:161–172
65. Jimenez SA (2013) Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol 2013:835948
66. Li Z, Jimenez SA (2011) Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum 63:2473–2483
67. ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S (2009) Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 98:265–267
68. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM (2008) Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 47:735–737
69. ten Freyhaus H, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S (2012) Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 21:119–134
70. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115
71. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C et al (1995) Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91:1314–1319
72. Peng X, Haldar S, Deshpande S, Irani K, Kass DA (2003) Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium. Hypertension 41:378–381
73. Li M, Chiou KR, Bugayenko A, Irani K, Kass DA (2005) Reduced wall compliance suppresses Akt-dependent apoptosis protection stimulated by pulse perfusion. Circ Res 97:587–595
74. Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S (1998) Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol 82(1555–1557):A8
75. Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I et al (1998) Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud’s phenomenon. Am Heart J 136:905–912
76. Szucs G, Tímár O, Szekanecz Z, Dér H, Kerekes G, Szamosi S et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatology (Oxford) 46:759–762
77. Bartoli F, Blagojevic J, Bacci M, Fiori G, Tempestini A, Conforti ML et al (2007) Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci 1108:283–290
78. Rollando D, Bezante GP, Sulli A, Balbi M, Panico N, Pizzorni C et al (2010) Brachial artery endothelial-dependent flow-mediated dilation identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol 37:1168–1173
79. Rossi P, Granel B, Marziale D, Le Mée F, Francès Y (2010) Endothelial function and hemodynamics in systemic sclerosis. Clin Physiol Funct Imaging 30:453–459
80. Cypiene A, Laucevicius A, Venalis A, Dadoniene J, Ryliskyte L, Petrulioniene Z et al (2008) The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol 27:1517–1522
81. Giannattasio C, Pozzi M, Gardinali M, Gradinali M, Montemerlo E, Citterio F et al (2007) Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. J Hypertens 25:793–797
82. Cotton SA, Herrick AL, Jayson MI, Freemont AJ (1999) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 189:273–278
83. Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M et al (2006) Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 45:676–684
84. Andersen GN, Mincheva-Nilsson L, Kazzam E, Nyberg G, Klintland N, Petersson AS et al (2002) Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 46:1324–1332
85. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H et al (1992) Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19(10):1566–1571
86. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838–1844
87. Marvi U, Chung L (2010) Digital ischemic loss in systemic sclerosis. Int J Rheumatol. doi:10.1155/2010/130717
88. Kahaleh MB (1994) Raynaud’s phenomenon and vascular disease in scleroderma. Curr Opin Rheumatol 6:621–627
89. Chung L, Fiorentino D (2006) Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 5:125–128
90. Schiopu E, Impens AJ, Phillips K (2010) Digital ischemia in scleroderma spectrum of diseases. Int J Rheumatol. doi:10.1155/2010/923743
91. Noda S, Asano Y, Nishimura S, Taniguchi T, Fujiu K, Manabe I et al (2014) Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 5:5797
92. Kundi R, Hollenbeck ST, Yamanouchi D, Herman BC, Edlin R, Ryer EJ et al (2009) Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc Res 84:326–335
93. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666
94. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970
95. Mouthon L, Berezne A, Guillevin L, Valeyre D (2010) Therapeutic options for systemic sclerosis related interstitial lung diseases. Respir Med 104(Suppl 1):S59–S69
96. Sakkas LI, Chikanza IC, Platsoucas CD (2006) Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2:679–685
97. Casale R, Generini S, Luppi F, Pignone A, Matucci-Cerinic M (2004) Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud’s phenomenon) in a case of early systemic sclerosis. Arthritis Rheum 51:665–669
98. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC et al (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48:2256–2261
99. Caramaschi P, Volpe A, Pieropan S, Tinazzi I, Mahamid H, Bambara LM et al (2009) Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. Clin Rheumatol 28:391–395
100. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, Kuwana M (2010) Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheumatology (Oxford) 49:2375–2380
101. Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A et al (2013) Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 106:839–848
102. Frerix M, Stegbauer J, Dragun D, Kreuter A, Weiner SM (2012) Ulnar artery occlusion is predictive of digital ulcers in SSc: a duplex sonography study. Rheumatology (Oxford) 51:735–742
103. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32–38
104. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993
105. Ichimura Y, Asano Y, Hatano M, Tamaki Z, Takekoshi T, Kogure A et al (2011) Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene. Mod Rheumatol 21:548–552
106. Abdelsaid M, Kaczmarek J, Coucha M, Ergul A (2014) Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control. Life Sci 118:268–273
107. Dréau D, Karaa A, Culberson C, Wyan H, McKillop IH, Clemens MG (2006) Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis 23:41–53
108. Guiducci S, Bellando Randone S, Bruni C, Carnesecchi G, Maresta A, Iannone F et al (2012) Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31:1723–1725
109. Cutolo M, Zampogna G, Vremis L, Smith V, Pizzorni C, Sulli A (2013) Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 40:40–45
110. Akamata K, Asano Y, Yamashita T, Noda S, Taniguchi T, Takahashi T et al (2015) Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli1 knockout mice by increasing Fli1 DNA-binding ability. Arthr Rheumatol. doi:10.1002/art.39062
111. Asano Y, Trojanowska M (2009) Phosphorylation of Fli1 at threonine 312 by protein kinase C δ promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor β. Mol Cell Biol 29:1882–1894
112. Asano Y, Czuwara J, Trojanowska M (2007) Transforming growth factor-β regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 282:34672–34683
113. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM et al (2003) Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 163:571–581
114. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y et al (2014) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204522
115. Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Takahashi T et al (2014) Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 41:418–420
116. Khor CG, Chen XL, Lin TS, Lu CH, Hsieh SC (2014) Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Clin Rheumatol 33:1019–1020
117. Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP (2012) Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 41:822–829
118. Maslyanskiy AL, Lapin SV, Kolesova EP, Penin IN, Cheshuina MD, Feist E et al (2014) Effects of rituximab therapy on elastic properties of vascular wall in patients with progressive systemic sclerosis. Clin Exp Rheumatol 32(6 Suppl 86):S-228